Login to Your Account

Financings Roundup

Selecta's Series B Adds $15M to Advance Targeted Nanoparticles

By Jennifer Boggs

Thursday, February 26, 2009
Founded in late 2007 to develop a technology platform that combines discoveries in immunobiology with advances in nanotechnology, Selecta Biosciences Inc. is ready to start moving its program toward the clinic thanks to a $15.1 million Series B round. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription